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An insertion polymorphism of the angiotensin-I converting en-
zyme gene (ACE) is common in humans and the higher expressing
allele is associated with an increased risk of diabetic complications.
The ACE polymorphism does not significantly affect blood pres-
sure or angiotensin II levels, suggesting that the kallikrein-kinin
system partly mediates the effects of the polymorphism. We have
therefore explored the influence of lack of both bradykinin recep-
tors (B1R and B2R) on diabetic nephropathy, neuropathy, and os-
teopathy in male mice heterozygous for the Akita diabetogenic
mutation in the insulin 2 gene (Ins2). We find that all of the det-
rimental phenotypes observed in Akita diabetes are enhanced by
lack of both B1R and B2R, including urinary albumin excretion,
glomerulosclerosis, glomerular basement membrane thickening,
mitochondrial DNA deletions, reduction of nerve conduction ve-
locities and of heat sensation, and bone mineral loss. Absence of
the bradykinin receptors also enhances the diabetes-associated
increases in plasma thiobarbituric acid-reactive substances, mito-
chondrial DNA deletions, and renal expression of fibrogenic genes,
including transforming growth factor beta1, connective tissue
growth factor, and endothelin-1. Thus, lack of B1R and B2R exac-
erbates diabetic complications. The enhanced renal injury in dia-
betic mice caused by lack of B1R and B2R may be mediated by
a combination of increases in oxidative stress, mitochondrial
DNA damage and over expression of fibrogenic genes.
diabetes mellitus complications | kinins
The angiotensin-I converting enzyme (ACE) is a dipeptidylcarboxypeptidase, named because it removes two amino acids
from the carboxyl terminus of the inactive peptide angiotensin I
and converts it into the active blood pressure-raising peptide,
angiotensin II. However, ACE is also a kininase and converts the
active vasodilatory kinins into inactive metabolites by removing
two amino acids from their carboxyl termini (1). Prior experi-
mental findings (2) and computer simulations (3) show that
modest changes in ACE levels affect the levels of its substrates
much more than its products, indicating that relatively small
changes in the levels of ACE affect kinin levels more than an-
giotensin II levels.
The common insertion/deletion (I/D) polymorphism of the
ACE gene in humans is due to the presence or absence of an Alu
retrotransposon in the 16th intron of the gene. The poly-
morphism is associated with up to a twofold difference in relative
plasma ACE levels (4), but the polymorphism does not signifi-
cantly affect blood pressure or angiotensin II or aldosterone
levels (5). Nevertheless, the I and D human ACE alleles are
associated with different risks for developing diabetic compli-
cations including nephropathy (6), neuropathy (7), retinopathy
(8), myocardial infarction (9), stroke (10), and osteoporosis (11).
In all these diabetes-associated conditions, it is the D allele,
associated with higher serum levels of ACE, that confers the
increased risk. Acting in the reverse direction, ACE inhibitors
(ACEIs) have well-documented beneficial effects on diabetic
nephropathy (12), diabetic neuropathy (13), diabetic retinopathy
(14), osteoporosis (15, 16), and coronary artery diseases (17) that
exceed what can be attributed solely to changes in blood pres-
sure. These findings suggest that the kallikrein-kinin system
(KKS) may partly mediate the protective effects of low levels of
ACE on diabetic complications and that reduced levels of the
kinins mediate some of the harmful effects of the ACE D allele.
In support of this postulate, a recent study has demonstrated that
lack of tissue kallikrein gene increases microalbuminuria in
a mouse model of type I diabetes (18). In addition, we have
demonstrated that genetically diabetic mice that also lack one of
the bradykinin receptors, B2R, develop a more severe kidney
pathology by age 6 months than their diabetic littermates
expressing B2R (19). By age 12 months, they develop senes-
cence-associated phenotypes that are more severe than those in
their diabetic littermates that have the B2R, including alopecia,
skin atrophy, kyphosis, osteoporosis, testicular atrophy, lip-
ofuscin accumulation in renal proximal tubule and testicular
Leydig cells, and apoptosis in the testis and intestine (20).
The other bradykinin receptor, B1R, is expressed atmuch lower
levels than B2R in the kidney of WT mice, but its expression is
markedly enhanced in the kidney of Akita diabetic or B2R
knocked out (B2R-null) mice (19). Whether this increase in B1R
expression is beneficial or harmful is debatable (21, 22). Because
the loci coding for B1R and B2R are only 11 kb apart, it is im-
practical to make mice lacking both B1R and B2R by simply
crossbreeding B1R-null mice and B2R-null mice. Consequently,
to unambiguously explore the role of KKS, we have generated
mice lacking both receptors (BRKO) by deleting the genomic
region that includes both genes (23). (There are no identified or
predicted ORFs between the loci for B1R and B2R.) Another
group has generated BRKO mice by disrupting B1R using em-
bryonic stem (ES) cells obtained from B2R-null mice (24) and
have shown that the response to kinins, as attested by contractility
studies in smooth muscle cells, is lacking, indicating that signaling
via B1R and B2R mediates most of the effects of the kinins.
Here, we show that the lack of both B1R and B2R enhances the
nephropathy, neuropathy, and osteopathy observed in male mice
with the Akita diabetogenic mutation in the Insulin 2 gene (Ins2).
These results demonstrate that the KKS plays a protective role in
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these diabetic complications and suggest that vasopeptidase in-
hibitors and KKS agonists, like ACE inhibitors, could be benefi-
cial for treatment or prevention of diabetic complications.
Results
Baseline Effects of Lack of Bradykinin B1 and B2 Receptors on Akita
Diabetic Mice. Table 1 shows baseline data at 12 months age of
WT male mice, mice with the gene coding for B2R knocked out
(B2R-null), mice with the genes coding for both B1R and B2R
knocked out (BRKO), mice heterozygous for the diabetogenic
Akita mutation in the Ins2 gene (Akita), Akita mice with the
gene coding for B2R knocked out (B2R-null-Akita), and Akita
mice with the genes coding for both bradykinin receptors
knocked out (BRKO-Akita). Table S1 lists the P values, assessed
by two-way ANOVA, for the effects on the various parameters of
bradykinin receptors genotype and the Akita mutation and for
the presence of any interaction between them. The data show
that the bradykinin receptor mutations by themselves affect only
two of the baseline parameters: plasma insulin levels (increased
to approximately 1.6× normal in B2R-null and approximately
2.5× normal in BRKO), and plasma thiobarbituric acid-reactive
substances (TBARS) (increased to approximately 2.6× normal in
B2R-null and approximately 3.0× normal in BRKO). Absence of
the receptors does not change systolic blood pressure. The Akita
mutation by itself has many of the expected effects of untreated
type I diabetes: decreased body weight (BW) and heart weight
(HW), increased kidney to body weight ratio (KW/BW), and
increased plasma glucose, plasma triglycerides, and plasma
TBARSs. It has no significant effect on systolic blood pressure.
When the bradykinin receptor mutations and the Ins2 mutation
are combined in the B2R-null-Akita or BRKO-Akita mice, there
is a marked additive increase in plasma TBARSs (to approxi-
mately 4.6× normal in B2R-null and approximately 5.8× normal
in BRKO). Not surprisingly, the high plasma insulin levels
caused by the BRKO mutation are abolished by the profound
decrease in insulin production that is a consequence of the Akita
mutation. The BRKO mutation does not modify the effects of
the Akita diabetogenic mutation on BW, HW, KW/BW, plasma
glucose, and plasma triglyceride. Thus, the most notable effect
on the diabetic profile of absence of the two bradykinin receptors
is that the already high level of plasma TBARSs caused by the
diabetes is additively increased to approximately five times nor-
mal, indicating a large increase in oxidative stress.
Lack of Bradykinin Receptors and Diabetic Nephropathy. Urinary
albumin excretion, already approximately 9.8× normal in the
Akita diabetic mice and approximately 1.8× and approximately
2.7× normal in the B2R-null and BRKO mice, is increased to
approximately 16.6× and approximately 29.0× normal in the
B2R-null and BRKO-Akita mice and there is a strong positive
interaction between the two mutations (P of interaction < 0.001;
Fig. 1). In light microscopy, mesangial hypercellularity, accu-
mulation of periodic acid-Schiff (PAS)-positive extracellular
matrix, intra-arteriolar hyalinosis (insudation) in the renal glo-
merulus (Fig. 2), and tubulointerstitial fibrosis (Fig. 3) are ob-
served in the Akita diabetic mice. The glomerular sclerosis and
interstitial fibrosis caused by Akita diabetes are markedly en-
hanced by lack of B2R and by lack of both receptors at the age of
12months, even though histological changes in the nondiabetic B2R-
null or BRKO mice are not remarkable at this age (Figs. 2 and 3).
Electronmicroscopyshows the thickeningof theglomerularbasement
membrane and foot process effacement of podocytes caused byAkita
diabetes. The thickening of basementmembrane in theAkita diabetic
mice is markedly enhanced by lack of B2R (approximately 2.9× nor-
mal) and by lack of both B1R and B2R (approximately 6.1× normal),
although lackof the receptors in theabsenceofdiabeteshas littleorno
effect (Fig. 4). The effects on glomerular basement membrane
thickening and podocyte effacement of combining the two mutations
aremore thanadditive, as are thealbuminuria, glomerulosclerosis and
interstitial fibrosis. Thus, the diabetic nephropathy in Akita mice is
superadditively enhanced by lack of bradykinin receptors.
Effect on Mitochondrial Mutation of Lack of Bradykinin Receptors and
Akita Diabetes. The D-17 deletion in mitochondrial DNA is an
index of DNA damage and has been shown to be increased by
aging in mice (25). Fig. S1 shows that its incidence is also in-
creased by Akita diabetes (approximately 5× normal) and by lack
of B1R and B2R (approximately 2× normal). The increase in
mitochondrial DNA deletion caused by Akita diabetes is en-
hanced by lack of the bradykinin receptors in a superadditive
manner (approximately 12× normal; P of interaction < 0.001).
Table 1. Baseline characteristics of the 6 genotypes of male animals at age 12 months
WT B2R-null BRKO Akita B2R-null-Akita BRKO-Akita
Number of mice 5 5 5 5 5 10
Body weight, g 32.0 ± 1.6 31.1 ± 1.2 37.4 ± 1.6 22.5 ± 1.3* 21.2 ± 1.5* 23.2 ± 1.4*
Kidney weight, mg 245 ± 19 237 ± 35 248 ± 17 239 ± 14 252 ± 10 255 ± 15
KW/BW, ‰ 7.80 ± 0.71 7.48 ± 0.89 6.81 ± 0.63 10.67 ± 0.50* 12.21 ± 0.96† 10.91 ± 0.54*
Heart weight, mg 238 ± 22 205 ± 21 184 ± 22 112 ± 4* 110 ± 8* 151 ± 18
HW/BW, ‰ 7.50 ± 0.76 6.60 ± 0.61 5.00 ± 0.76 5.75 ± 0.60 5.22 ± 0.17 6.42 ± 0.65
Glucose, mg/dL 142 ± 14 145 ± 9 154 ± 32 798 ± 58* 783 ± 44* 750 ± 32*
Insulin, μmol/L 0.59 ± 0.10 0.95 ± 0.10¶ 1.61 ± 0.10‡,§ 0.11 ± 0.08* 0.09 ± 0.05* 0.09 ± 0.08*
Urea nitrogen, mg/dL 20.3 ± 1.4 22.1 ± 2.8 22.8 ± 3.0 32.3 ± 4.2 35.6 ± 2.8† 25.8 ± 2.8
Creatitine, mg/dL 0.10 ± 0.03 0.16 ± 0.04 0.12 ± 0.03 0.14 ± 0.03 0.18 ± 0.03 0.13 ± 0.03
Total cholesterol, mg/dL 54.9 ± 9.0 105.9 ± 10.9 85.8 ± 9.0 77.7 ± 7.1 62.9 ± 13.1 67.3 ± 7.6
Triglyceride, mg/dL 55.1 ± 25.1 76.4 ± 14.5 48.1 ± 25.1 105.8 ± 19.8 93.0 ± 27.6 133.8 ± 21.2†
TBARSs, mmol/L 6.5 ± 1.0 17.2 ± 1.6‡ 19.0 ± 2.6‡ 22.5 ± 1.2* 29.7 ± 2.0¶,* 37.9 ± 2.0‡,§,*
Systolic BP, mmHg 108 ± 3 113 ± 1 114 ± 5 115 ± 2 115 ± 2 115 ± 3
Data are shown as mean ± SEs. WT, wild type; B2R-null, mice lacking B2R; BRKO, mice lacking both B1R and B2R; Akita, mice with
heterozygous Akita mutation in Ins2 gene; B2R-null-Akita, B2R-null mice with heterozygous Akita mutation in Ins2 gene; BRKO-Akita,
BRKO mice with heterozygous Akita mutation in Ins2 gene; TBARSs, thiobarbituric acid-reactive substances; BP, blood pressure.
*P < 0.01 vs. the nondiabetic group of the same bradykinin receptor genotype;
†P < 0.05 vs. the nondiabetic group of the same bradykinin receptor genotype;
‡P < 0.01 vs. WT (in nondiabetic groups) or Akita (in diabetic groups);
§P < 0.05 vs. B2R-null (in nondiabetic groups) or B2R-null-Akita (in diabetic groups);
¶P < 0.05 vs. WT (in nondiabetic groups) or Akita (in diabetic groups).






























Effect of Lack of Bradykinin Receptors and Akita Diabetes on Renal
Expression of Fibrogenic Genes. Expression of transforming growth
factor β1 (TGFβ1), connective tissue growth factor (CTGF) and
endothelin-1 (EDN1) is known to be increased in diabetic ne-
phropathy (26–28). Furthermore, in vivo overexpression of TGFβ1
(29), CTGF (30), or EDN1 (31) is associated with the development
of nephrosclerosis (26–28), suggesting that overexpression of these
genes contributes to the pathogenesis of diabetic nephropathy.
Fig. S2 shows that the levels of mRNAs for these genes are greater
in the kidney in BRKO Akita mice than in Akita mice at age 12
months and that this effect is also superadditive (Fig. S2). The
increased incidence of mitochondrial mutations and in the ex-
pression of these fibrogenic genes is relevant to the enhanced di-
abetic nephropathy of the BRKO-Akita mice.
Lack of Bradykinin Receptors and Diabetes-Induced Osteoporosis.
Bone mineral loss is another serious complication of type I di-
abetes (32). Fig. 5 shows bone mineral density determined with
dual emission x-ray absorptiometry (DEXA) at age 12 months.
Both the Akita diabetic mice and the BRKO mice have densities
very significantly less than WT mice. The BRKO-Akita mice
have still lower bone mineral densities, although the effects of
the two mutations are less than additive (P of negative in-
teraction < 0.005).
Lack of Bradykinin Receptors and Diabetic Neuropathy. We have
previously reported that Akita diabetic mice on a C57BL/6 ge-
netic background are resistant to diabetic neuropathy, as judged
by the minimal effects of Akita diabetes on latencies of heat
sensation and nerve conduction velocity at age 24 weeks (33).
Nevertheless, at the same age and on the same genetic back-
ground, the response times to a thermal stimulus (tail flick and
hind paw withdrawal) are prolonged in the BRKO-Akita mice
relative to the Akita, BRKO, or WT mice (Fig. 6). Likewise,
nerve conductance velocities of the BRKO-Akita mice are less
than in the other three genotypes (Fig. 6). Thus, concomitant
absence of bradykinin receptors induces a neuropathy not oth-
erwise observed in diabetic Akita mice.
Discussion
Kinins and their derivatives generated from kininogens by kal-








Fig. 2. Histopathology of kidneys in 12-month-old male WT, B2R-null,
BRKO, Akita, B2R-null-Akita, and BRKO-Akita mice. Absence of bradykinin
receptors enhances renal histological changes in Akita diabetic mice. PAS
staining of renal glomeruli and glomerulosclerosis index. Lack of bradykinin







Fig. 3. Gomori’s trichrome staining of renal cortex and interstitial fibrosis
score. Absence of bradykinin receptors increases the interstitial fibrosis in
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Fig. 1. Urinary albumin excretion in 12-month-old male WT mice (n = 5),
mice with a null mutation in the gene coding for B2R (B2R-null; n = 5), mice
with a null mutation in the genes coding for B1R and B2R (BRKO; n = 5), mice
heterozygous for the Akita mutation in the Ins2 gene (Akita; n = 5), B2R-null
mice heterozygous for Akita mutation (B2R-null-Akita; n = 5), and BRKO
mice heterozygous for Akita mutation (BRKO-Akita; n = 10). Absence of B2R
or of both B1R and B2R increases urinary albumin excretion in Akita diabetic
mice. Urinary albumin excretion is significantly higher in Akita mice lacking
both B1R and B2R than in Akita mice lacking B2R. Data are presented as
means ± SEs. P interaction (Methods) is the P value for interaction of the
effects of bradykinin receptor genotypes and Akita mutation.




















date, two receptors for kinins have been identified in mammals:
B1R and B2R. Whereas B2R is constitutively expressed, B1R is
expressed at only low levels in normal tissues, but it is induced
following tissue injury or after treatment with endotoxins or
cytokines (34). Both B1R and B2R are overexpressed in ische-
mia and diabetes mellitus (19, 35). B1R is also markedly induced
in the absence of B2R (19, 36), suggesting some functional re-
dundancy between the two receptors.
Both the receptors are coupled with Gq-proteins (34), and
their stimulation activates phosphatidylinositol-specific phos-
pholipases, which elevates intracellular [Ca2+] and leads to ac-
tivation of endothelial nitric oxide synthase (eNOS) (37, 38). The
kinins, acting through B2R also increase the expression of in-
ducible NOS (iNOS) (39). Our previous finding that preprandial
levels of plasma nitrite/nitrate are lower in BRKO mice than in
WT (23), and another report showing that urinary nitrite/nitrate
excretion in B2R-null mice is lower than in WT (40) suggest that
the KKS is also important in basal NO production.
NO reversibly suppresses mitochondrial oxidative metabolism
(41), at least in part by inhibiting cytochrome c oxidase, which is
a key enzyme in the electron transport chain (42). Kinins also fa-
cilitate the synthesis of prostanoids, including prostaglandin (PG)
E2 and I2, which elevate intracellular cAMP levels (43). Recent
studies have shown that cAMP decreases mitochondrial respira-
tion by activating the NADH-ubiquinone oxidoreductase activity
of complex I and by inhibiting cytochrome c oxidase (44, 45). Thus,
it is likely that the KKS contributes to reducing oxidative stress via
NO and PGs. In support of this possibility, we have shown that
bradykinin reduces mitochondrial superoxide generation in hu-
man EA.hy926 vascular endothelial cells, an effect that is partly
reversed by an NOS inhibitor (20). When bradykinin is adminis-
tered to ratsmade hyperglycemicwith streptozotocin (STZ), it also
reduces their oxidative stress phenotype, as judged by hydrogen
peroxide and malondialdehyde levels (46).
We have previously reported that absence of the predominant
bradykinin receptor, B2R, exacerbates many of the pathologic con-
sequences of diabetes (19) and induces premature aging (20). The
interpretation of these findings with respect to the KKS is compli-
cated by amarked increase in the expression of the other bradykinin
receptor, B1R, which is normally expressed at low levels but is in-
duced by absence of B2R, by diabetes, and by their combination.
In our present study, we observe that the pathological changes
characteristic of Akita diabetes, including albuminuria, renal
histopathology, bone mineral loss, and neuropathy, are all en-
hanced in the BRKO-Akita mice that lack both bradykinin
receptors. The enhancement of albuminuria and renal histopa-
thology in Akita mice caused by absence of both receptors is
greater than that in Akita mice lacking only B2R, thus estab-
lishing that expression of B1R has beneficial effects in the B2R-
Akita mice. The effects on any particular phenotype of com-
bining the BRKO and Akita mutations may be simply additive,
more than additive, or less than additive. But, even when the two
mutations combine less than additively, the pathology observed
in the BRKO-Akita mice is invariably worse than that in either
the Akita or the BRKO animals. The renal diabetic phenotype
(including albuminuria, interstitial fibrosis, and glomerular
basement membrane thickening) is most sensitive to the BRKO-
Akita combination, even though the BRKO mice exhibit mini-
mal renal pathology.
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Fig. 5. Bone mineral density. Densities were assessed with dual emission
x-ray absorptiometry in 12-month-old male WT (n = 5), Akita (n = 5), BRKO
(n = 5), and BRKO Akita (n = 10) mice. Absence of bradykinin receptors
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Fig. 6. Neurological status measurements made in 6-month-old male WT
(n = 5), Akita (n = 8), BRKO (n = 8), and BRKO Akita (n = 10) mice. Hind paw,
reaction time for hind paw withdrawal; Tail flick, reaction time for tail flick;
sciatic motor NCV, sciatic motor nerve conduction velocity; sural NCV, sural
(sensory) nerve conduction velocity. Absence of bradykinin receptors en-
hances neuropathy in Akita diabetic mice.
Fig. 4. Electron micrographs of glomeruli. Lack of bradykinin receptors
enhances the increase in the thickness of basement membrane occurring in
diabetic mice. (Scale bar, 1 μm.)






























The expression of TGFβ1, CTGF, and EDN1 is increased in
diabetic nephropathy (26–28), and glomerulonephritis has been
reported in albumin promoter-driven TGFβ1 transgenic mice,
which have more than 10-fold TGFβ1 levels of controls (29).
Transgenic expression in mice of EDN1 driven by its own pro-
moter is associated with age-dependent development of glo-
merulosclerosis (31). Furthermore, in streptozotocin-induced
diabetes, podocyte-specific CTGF overexpression causes en-
hanced proteinuria and glomerular mesangial expansion (30).
Here we find that the renal expressions of TGFβ1, CTGF, and
EDN1 are all increased in the mice made diabetic with the Akita
mutation. The BRKO mutation also increases the expression of
these genes when alone or when combined with the Akita mu-
tation, and the BRKO-Akita combination of the two mutations
increases the expression of TGFβ1 superadditively and that of
CTGF and EDN1 additively. The increased expression of these
fibrogenic genes probably contributes to the enhanced diabetic
nephropathy we find in the BRKO-Akita mice.
Thus far, the effect of KKS on the neuropathy induced by
long-lasting diabetes has been focused on the suppressive effect
of B1R on diabetic hyperalgesia (47). However, another im-
portant aspect of diabetic neuropathy is the hypoalgesia caused
by polyneuropathy in peripheral nerves, which can lead to lower
limb amputations that have a major impact on the quality of life
and disability of diabetic patients (48). In the present study, we
find that response times to thermal stimuli are increased in the
BRKO-Akita mice relative to either the simply diabetic Akita
mice or the BRKO mice. Nerve conduction velocities of the
BRKO-Akita mice are also decreased by the combination of
diabetes and absence of the bradykinin receptors, in this case
more than additively, thus demonstrating the importance of the
KKS in minimizing the neurological effects of diabetes.
Osteoporosis is a well established manifestation of aging. It is
also one of complications in type I diabetes (32), although the
mechanisms leading to this osteoporosis are not clear. We find
that lack of both bradykinin receptors results in a severe re-
duction in bone mineral density both in Akita diabetic and non-
diabetic mice, demonstrating the importance of the KKS in bone
mineralization. However, although osteoblasts express both B1R
and B2R, their stimulation with bradykinin increases expression
of the receptor activator for NF-κB ligand, which is known to be
involved in osteoclastogenesis (49). This in vitro observation
consequently suggests that acute stimulation of KKS can cause
bone resorption. In contrast to these results with cultured cells,
we find that lack of either B2R (20) or of both B1R and B2R
decreases bone mineral density in living mice. The reason for the
discrepancy between the results of the in vitro experiments and
our current in vivo experiments is unclear, although the concen-
tration of bradykinin used in the tissue culture system (3 μM) is
much greater than that encountered in vivo (<1 pM) (50).
Several of our findings are relevant to the mechanism un-
derlying the effects of an impaired KKS on the complications
induced by diabetes. The first finding is that BRKO mice are
insulin resistant, which is in agreement with a previous report that
B2R-null mice are insulin-resistant (51). Thus the KKS may play
an important role in insulin sensitivity in mice. When the Akita
mutation is added to the BRKO mutation, the development of
high insulin levels is prevented, consequently the two mutations
interact negatively on insulin levels in the BRKO-Akita mice. In
contrast, the increase in plasma TBARSs caused by the BRKO
mutation is additively increased by the Akita mutation. Finding
increased oxidative stress, detected as the increase in plasma
TBARSs, suggests that oxidative stress is a second factor leading
to the pathological changes that are exhibited by these mice.
An additional factor that impinges on the pathology of the
BRKO-Akita mice, particularly the renal pathology, is a marked
increase in renal mitochondrial damage. The combined enhancing
effects of the BRKO mutation on the increased renal mitochon-
drial damage and increased renal expression of fibrogenic genes
already caused by diabetes are likely explanations for our finding
that the kidney is particularly sensitive to the BRKO mutation.
In conclusion, absence of both bradykinin receptors enhances
the nephropathy, neuropathy, and bone mineral loss caused by
insulin-dependent diabetes in mice, together with increased oxi-
dative stress, mitochondrial mutations, and expression of fibro-
genic genes. These results demonstrate that B1R and B2R
moderate the development of complications in diabetic mice and
suggest that activation of KKS could be beneficial in reducing the
severity of complications in diabetic patients, particularly those
carrying the D allele of the ACE gene.
Methods
Animals. Mice lacking B2R gene or having the diabetogenic Akita mutation
(C96Y) in the insulin 2 geneof theC57BL/6 strainwere purchased from Jackson
Laboratory.Mice lackingbothB1RandB2RofapureC57BL/6backgroundwere
generated as previously described (23). All experiments were approved by the
University of North Carolina Institutional Animal Care and Use Committee.
Bone mineral densities in femurs were measured with DEXA (LUNAR PIX-
Imus2; GE Healthcare) in the Body Composition Core of the Clinical Nutrition
Research Center at the University of North Carolina. Systolic blood pressures
and pulse rates were measured with the tail-cuff method (52).
Measurement of Biochemical Parameters. Mice were anesthetized with 2.5%
isoflurane, and blood was collected from retro-orbital sinuses with heparin-
izedglass pipettes (Fisher Scientific). The sampleswere centrifuged (7,000g for
5 min) to separate plasma. Plasma samples were frozen and stored at –80 °C
before analysis for biochemical parameters. Plasma glucose levels were de-
terminedwith the glucose oxidasemethod (Wako Chemical USA, Inc.). Plasma
insulin levels were determined with ELISA (Crystal Chem Inc.). Plasma urea
nitrogen and creatinine concentrations were determined with the Vitros
250 Chemistry system (Ortho-Clinical Diagnostics). Plasma total cholesterol
(Wako) and triglyceride (Stanbio Laboratory) were measured with enzymatic
colorimetric methods. Plasma levels of TBARSs were determined as described
(53). Urinary albumin was determined with ELISA (Albuwell M; Exocell).
Sensory Testing, Tail Flick, and Hind Paw Withdrawal. Thermal sensitivities
were determinedwith an analgesia apparatus (Model 336TG; Life Sciences) as
previously described (33). Tail flick responses were elicited with an adjustable
red light emitter (range 60–170 °C), and the time for the animal to respond
was recorded electronically. For hind paw withdrawal times, the mice were
placed in compartments on a warm (32 °C) glass plate and allowed to ha-
bituate for 10 min. The light source was maneuvered under the hind paw,
and the time to paw withdrawal was recorded. The light source was set at
25 °C and the temperature increased to 70 °C over the course of 10 s. A
threshold of 10 s was applied to prevent injury to the mice.
Measurement of Nerve Conduction Velocity. Sciatic motor nerve conduction
velocity (SMNCV) and sural nerve conduction velocity (Sural NCV) were
assessed as previously described (54). Briefly, animals were anesthetized with
30/2.5 mg/kg i.p. ketamine:xylazine. Hind limb skin temperature was moni-
tored using a thermistor and was maintained at approximately 34 °C with
awarming lamp. SMNCVwas recorded by stimulating proximally at the sciatic
notch and distally at the ankle. Sural NCV was determined by stimulating the
sural nerve distally at the ankle and recording at the fourth and fifth digit.
Conduction velocity was calculated using the onset latency and distance.
Histological Evaluation. The left kidney and heart were fixed with 4% (wt/vol)
paraformaldehyde. Tissues were embedded in paraffin, stained with PAS
reagent and hematoxylin or with Gomori’s Trichrome reagent, and examined
under an optical microscope. Renal tissue was also examined under an
electron microscope after fixation with 15% (wt/vol) glutalaldehyde. The
glomerulosclerosis index and interstitial fibrosis score were evaluated in
a blind fashion as previously described (55, 56).
Quantitative RT-PCR. Total RNA was extracted from the kidney and heart.
mRNAs for TGFβ1, CTGF, and EDN1 were assayed by quantitative reverse
transcription-PCR as previously described (20).
Quantification of Mitochondrial DNA Deletion Mutants. Large deletions be-
tween two homologous sequences in mtDNA have been reported in mice
(25). We assayed the most common deletion mutation, D-17, in renal mtDNA




















samples using quantitative PCR with primers flanking the D-17 deletion and
with the template mtDNAs cut at an Mlu I site present in the region deleted
in D-17 as previously described (20).
Statistical Analysis. Data are expressed as means ± SEs. To compare groups,
we used the two-way ANOVA by least-square fit to determine the signifi-
cance of the effects of and interactions between the two categorical
parameters: bradykinin receptor genotype (WT, B2R-null, or BRKO) and the
Akita heterozygous mutation in the Ins2 gene (Figs. 1–6, Figs. S1 and S2, and
Table S1). Posthoc pairwise comparisons were by the Student’s t test (JMP
6.0.0; SAS Institute Inc.).
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